Evaluated : Actualité Evaluated en direct - P1 | Bourse Reflex
Accueil > Tags > Evaluated

  • Toutes les actualités en rapport avec « Evaluated »

06/04 07:00 Evaluated - FUTUREN increased its revenue and EBITDA in 2017. Nevertheless, the net result is negative because of non-recurring items

24/03 18:00 Evaluated - With a net profit of 2.8 million euros in 2016, FUTUREN confirms its profitability and demonstrates the strength of its fundamentals

22/12 13:00 Evaluated - Genticel and Genkyotex Announce Intention to Enter into Strategic Combination

29/09 17:45 Evaluated - Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension

12/09 18:00 Evaluated - Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016

08/08 18:35 Evaluated - Disclosure of the total number of voting rights and shares composing the share capital

08/08 18:35 Evaluated - HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

28/07 18:35 Evaluated - BUSINESS UPDATE - SECOND QUARTER 2016

07/07 19:30 Evaluated - Disclosure of the total number of voting rights and shares composing the share capital

06/07 18:35 Evaluated - GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES

23/06 17:45 Evaluated - GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

13/06 18:35 Evaluated - GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

17/05 18:00 Evaluated - Quantum Genomics granted two new U.S. patents covering lead product QGC001

28/04 18:35 Evaluated - BUSINESS UPDATE - FIRST QUARTER 2016

26/04 18:00 Evaluated - Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure

20/04 18:30 Evaluated - GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

14/03 07:00 Evaluated - GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016

27/01 18:40 Evaluated - GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

07/01 07:30 Evaluated - GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS(R) HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

02/12 18:30 Evaluated - SES wins the largest ESL project ever in the market